Neuroprotection of acetylcholinergic basal forebrain neurons by memantine and neurokinin B

Behavioural Brain Research

Volumn 83, Issue 1-2, 1997, Pages 129-133

  Wenk, Gary L ^a,b   Zajaczkowski, Wojciech ^a,b   Danysz, Wojciech ^a,b  

^a UNIVERSITY OF ARIZONA   (United States)

^b MERZ PHARMACEUTICALS GMBH   (Germany)

Author keywords

entorhinal cortex; lesion; memantine; N methyl D aspartate; neurokinin B; nucleus basalis magnocellularis

Indexed keywords

BACITRACIN; CHOLINE ACETYLTRANSFERASE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID; NEUROKININ B; NOOTROPIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; BRAIN INJURY; COGNITIVE DEFECT; CONFERENCE PAPER; CONTROLLED STUDY; MALE; MAZE TEST; NONHUMAN; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031081014     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-4328(97)86056-1     Document Type: Conference Paper

References (28)

1. [1] Bartus, R.T., Dean, R.L., Beer, B. and Lippa, A.S., The cholinergic hypothesis of geriatric memory dysfunction, Science, 217 (1982) 408-417.
2. [2] Burgunder, J-M. and Young, W.S., Neurons with neurokinin B mRNA in the rat magnocellular basal nucleus: distribution, projection and colocalization studies, J. Chem. Neuroanat., 2 (1989) 239-251.
3. [3] Chawla, M.K., Gutierrez, G.M., Wenk, G.L. and Rance, N.E., Choline acetyltransferase and neurokinin B mRNAs are colocalized in neurons of the human magnocellular basal forebrain complex, Soc. Neurosci. Abstr. 25 (1995).
4. [4] Chen, H.S.V. and Lipton, A., Open channel block of NMDA responses by the antiparkinsonian drug memantine, Soc. Neurosci. Abstr., 17 (1991) 1292.
5. [5] Choi, D.W., Glutamate neurotoxicity and diseases of the nervous system, Neuron, 1 (1988) 623-634.
6. [6] Choi, D.W., Koh, J. and Peters, S., (1988). Pharmacology of glutamate neurotoxicity in cortical cell culture: Attenuation by NMDA antagonists, J. Neurosci., 8 (1988) 185-196.
7. [7] Collingridge, G.L. and Singer, W., Excitatory amino acid receptors and synaptic plasticity, Trends Pharmacol. Sci., 11 (1990) 290-296.
8. [8] Coyle, J.T., Price, D.L. and DeLong, M.R., Alzheimer's disease: A disorder of cortical cholinergic innervation, Science, 219 (1983) 1184-1190.
9. [9] Danysz, W., Zajaczkowski, W. and Parsons, C.G., Modulation of learning processes by ionotropic glutamate receptor ligands, Behav. Pharmacol. (1995) in press.
10. [10] Ditzler, K., Efficacy and tolerability of memantine in patients with dementia syndrome, Arzeneim-Forsch/Drug Res., 41 (1991) 773-781.
11. [11] Erdo, S.L. and Schafer, M., Memantine is highly potent in protecting cortical cultures against excitotoxic cell death evoked by glutamate and N-methyl-D-aspartate, Eur. J. Pharmacol., 198 (1991) 215-217.
12. [12] Fonnum, F., Radiochemical micro assays for the determination of choline acetyltransferase and acetylcholinesterase activities, Biochem. J., 115 (1969) 465-472.
13. [13] Gortelmeyer, R. and Erbler, H., Memantine in the treatment of mild to moderate dementia syndrome, Arzeneim-Forsch/Drug Res., 42 (1992) 904-913.
14. [14] Kaku, D.A., Giffard, R.G. and Choi, D.W., Neuroprotective effects of glutamate antagonists and extracellular acidity, Science, 260 (1993) 1516-1518.
15. 3H]MK-801 at therapeutic concentrations in post mortem human frontal cortex, Eur. J. Pharmacol., 166 (1989) 589-590.
16. [16] Kornhuber, J., Weller, M., Schoppmeyer, K. and Riederer, P., Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties, J. Neural Transm., (Suppl.), (1994) 91-104.
17. [17] Maggio, J.E., Tachykinins, Annu. Rev. Neurosci., 11 (1988) 13-28.
18. [18] Mesulam, M-M., Mufson, E.J., Levey, A.I. and Wainer, B.H., Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area diagonal band nuclei, nucleus basalis (substantia innominata) and hypothalamus in the rhesus monkeys, J. Comp. Neurol., 214 (1983) 170-197.
19. [19] Misztal, M., Frankiewicz, T., Parson, C.G. and Danysz, W., Learning deficit induced by chronic intraventricular infusion of quinolinic acid - protective effects of subcutaneous infusion of MK-801 and memantine, Eur. J. Pharmacol. (1995), submitted.
20. [20] Mondadori, C., Weiskrantz, L., Buerki, H., Petschke, F. and Fagg, G.E., NMDA receptor antagonists can enhance or impair learning in animals, Exp. Brain Res., 75 (1989) 449-456.
21. [21] Parson, C.G., Gruner, R., Rozental, J., Millar, J. and Lodge, D., Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan), Neuropharmacology, 32 (1993) 1337-1350.
22. [22] Warden, M.K. and Young, W.S. III, Distribution of cells containing mRNAs encoding substance P and neurokinin B in the rat central nervous system, J. Comp. Neurol., 272 (1988) 90-113.
23. [23] Wenk, G.L., Danysz, W. and Mobley, S.L., Investigations of neurotoxicity and neuroprotection within the nucleus basalis of the rat, Brain Res., 655 (1994) 7-11.
24. [24] Wenk, G.L., Danysz, W. and Mobley, S.L., MK-801, memantine and amantadine show neuroprotective activity in the nucleus basalis magnocellularis, Eur. J. Pharmacol. (1995), in press.
25. [25] Wenk, G.L., Harrington, C.A., Tucker, D.A., Rance, N.B. and Walker, L.C., Basal forebrain neurons and memory: A biochemical, histological and behavioral study of differential vulnerability to ibotenate and quisqualate, Behav. Neurosci., 106 (1992) 909-923.
26. [26] Wenk, G.L. and Olton, D.S., Basal forebrain cholinergic neurons and Alzheimer's disease. In: J.T. Coyle, (Ed.), Animal Models of Dementia: A Synaptic Neurochemical Perspective, Vol. 33: Neurology and Neurobiology, Alan R. Liss, New York, 1987, pp. 81-101.
27. [27] Wenk, G.L., Rance, N.E. and Mobley, S.L., Effects of excitatory amino acid lesions upon neurokinin B and acetylcholine neurons in the nucleus basalis of the rat. Brain Res., 679 (1995) 8-14.
28. [28] Yankner, B.A., Duffy, L.K. and Kirschner, D.A., Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides, Science, 250 (1990) 279-282.